{"preliminary_commentary":{"by_channel":{"x_thread":50,"bluesky_thread":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT07085728\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"EAA241","nct_id":"NCT07085728","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=eaa241-nct07085728. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Cyclophosphamide-Bortezomib-Dexamethasone (4 cycles)","label":"ARM A (Cy-Bor-Dex)","type":"ACTIVE_COMPARATOR"},{"description":"Daratumumab-Bortezomib-Dexamethasone","label":"ARM B (Dara-Bor-Dex)","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2038-09-11","type":"ESTIMATED"},"conditions":["Myeloma Multiple"],"enrollment":{"count":74,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Cyclophosphamide","otherNames":["Cytoxan","cyclophosphamide for injection"],"type":"DRUG"},{"name":"Bortezomib (VELCADE)","otherNames":["bortezomib injection (generic)","Velcade"],"type":"DRUG"},{"name":"Dexamethasone","otherNames":["Decadron"],"type":"DRUG"},{"name":"Daratumumab-hyaluronidase","otherNames":["Darzalex FASPRO®"],"type":"DRUG"}],"last_update":"2026-09-14","lead_sponsor":"Eastern Cooperative Oncology Group","official_title":"A Randomized Phase II Trial Comparing Daratumumab-Bortezomib-Dexamethasone Versus Cyclophosphamide-Bortezomib-Dexamethasone in Newly Diagnosed Multiple Myeloma With Light Chain Cast Nephropathy (LCCN)","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2029-01-11","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Renal Response Rate","timeFrame":"Assessed every cycle on treatment up to 4 cycles (cycle duration=28 days)"}],"references":[],"start_date":{"date":"2026-03-05","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure","url":"https://clinicaltrials.gov/study/NCT07085728"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/eaa241-nct07085728"}